In response to the World Health Organisation’s identification of contamination in its cough syrups, the Indian government has suspended the manufacturing license of a drugmaker. The contamination was found in cough syrups that were distributed in the Marshall Islands and Micronesia back in April. Indian regulators have been closely inspecting drugmakers after similar cough syrups produced in India were linked to the unfortunate deaths of 89 children in Gambia and Uzbekistan last year. This issue has raised concerns and tarnished India’s reputation as the “pharmacy of the world,” which has been known for providing affordable drugs globally.
The contamination flagged by the WHO included unacceptable levels of diethylene glycol and ethylene glycol, both of which are toxic to humans and can be fatal if ingested. The samples were taken from a batch of cough syrup manufactured by QP Pharmachem Ltd, a company based in the northern Punjab state. However, the company has refuted any allegations of wrongdoing.
According to these findings, the manufacturing licenses of QP Pharmachem Ltd, Marion Biotech Pvt. Ltd and Maiden Pharmaceuticals have been suspended, and their export activities have been halted.
Dear educhronicle.com admin, Your posts are always informative.
Dear educhronicle.com webmaster, Your posts are always well written.
To the educhronicle.com webmaster, You always provide in-depth analysis and understanding.